- Home
- UFCS vs PCRX Comparison
UFCS vs PCRX Comparison
Compare UFCS & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- PCRX
- Stock Information
- Founded
- UFCS 1946
- PCRX 2006
- Country
- UFCS United States
- PCRX United States
- Employees
- UFCS N/A
- PCRX N/A
- Industry
- UFCS Property-Casualty Insurers
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- PCRX Health Care
- Exchange
- UFCS Nasdaq
- PCRX Nasdaq
- Market Cap
- UFCS 642.7M
- PCRX 1.2B
- IPO Year
- UFCS N/A
- PCRX 2011
- Fundamental
- Price
- UFCS $25.29
- PCRX $26.80
- Analyst Decision
- UFCS Hold
- PCRX Buy
- Analyst Count
- UFCS 1
- PCRX 10
- Target Price
- UFCS $26.00
- PCRX $29.30
- AVG Volume (30 Days)
- UFCS 132.1K
- PCRX 892.8K
- Earning Date
- UFCS 02-11-2025
- PCRX 02-27-2025
- Dividend Yield
- UFCS 2.56%
- PCRX N/A
- EPS Growth
- UFCS N/A
- PCRX N/A
- EPS
- UFCS 1.94
- PCRX N/A
- Revenue
- UFCS $1,207,451,000.00
- PCRX $694,957,000.00
- Revenue This Year
- UFCS N/A
- PCRX $5.14
- Revenue Next Year
- UFCS $11.31
- PCRX $2.44
- P/E Ratio
- UFCS $12.86
- PCRX N/A
- Revenue Growth
- UFCS 10.95
- PCRX 4.40
- 52 Week Low
- UFCS $18.04
- PCRX $11.16
- 52 Week High
- UFCS $31.70
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- UFCS 34.07
- PCRX 77.75
- Support Level
- UFCS $24.11
- PCRX $25.06
- Resistance Level
- UFCS $26.15
- PCRX $27.10
- Average True Range (ATR)
- UFCS 0.82
- PCRX 1.45
- MACD
- UFCS -0.05
- PCRX 0.28
- Stochastic Oscillator
- UFCS 25.15
- PCRX 86.23
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.